Product development partnerships hit their stride: Lessons from developing a meningitis vaccine for Africa

Health Affairs

Volumn 30, Issue 6, 2011, Pages 1058-1064

  Bishai, David M ^a   Champion, Claire ^b   Steele, Michael E ^c   Thompson, Lindsay ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Bloomberg School   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGITIS VACCINE;

AFRICA; ARTICLE; BACTERIAL MENINGITIS; CHILD; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EPIDEMIC; FINANCIAL MANAGEMENT; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PROFIT; PUBLIC-PRIVATE PARTNERSHIP; VACCINATION; VACCINE PRODUCTION;

AFRICA; BACTERIAL VACCINES; COOPERATIVE BEHAVIOR; DISEASE OUTBREAKS; DRUG DISCOVERY; HUMANS; IMMUNIZATION PROGRAMS; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS, SEROGROUP A;

EID: 79959497102     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0295     Document Type: Article

References (18)

1. Moran M, Ropars A, Guzman J, Diaz J, Garrison C. The new landscape of neglected disease drug development [Internet]. London: Wellcome Trust; 2005 Sep [cited 2011 May 10]. Available from: http://www.wellcome.ac.uk/stellent/groups/corporatesite/@msh_publishing_group/documents/web_document/wtx026592.pdf.
2. Moran M, Guzman J, Henderson K, Ropars A, McDonald A, McSherry L, et al. Neglected disease research and development: new times, new trends [Internet]. Sydney: George Institute for International Health; 2009 Dec [cited 2011 May 10]. Available from: http://www.ghtcoalition.org/files/gfinder_dec2009.pdf.
3. International AIDS Vaccine Initiative. Innovative product development partnerships: advancing global health and economic development goals [Internet]. New York (NY): IAVI; 2010 Sep [cited 2011 May 10]. (Policy Brief No. 26). Available from: http://www.iavi.org/Lists/IAVIPublications/attachments/eb7b4247-6816-4094-9f54-9f2f2b99e95a/IAVI_Innovative_Product_Development_Partnerships_2010_ENG.pdf.
4. Bill & Melinda Gates Foundation. Global health strategy overview [Internet]. Seattle (WA): The Foundation; 2010 Sep [cited 2011 May 10]. Available from: http://www.gatesfoundation.org/global-health/Documents/global-health-strategyoverview.pdf.
5. Grace C. Product development partnerships (PDPs): lessons from PDPs established to develop new health technologies for neglected diseases [Internet]. London: UK Department for International Development; 2010 Jun 2 [cited 2011 May 10]. Available from: http://www.dfid.gov.uk/Documents/publications1/hdrc/lssns-pdps-estb-dev-new-hlth-technegl-diseases.pdf.
6. LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine. 2007;25(Suppl 1): A97-100.
7. Jódar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. The real cost of an affordable vaccine for meningococcus A. Lancet. 2003; 362(9379):251.
8. Rappuoli R. The real cost of an affordable vaccine for meningococcus A. Lancet. 2003;362(9379):250-1.
9. World Health Organization. Joint recommendations for the development and introduction of conjugate vaccines against meningococcal disease in the African and eastern Mediterranean regions. Geneva: WHO; 2000.
10. Schneerson R, Levi L, Robbins JB, Bryla DM, Schiffman G, Lagergard T. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect Immun. 1992;60(9):3528-32.
11. Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, et al. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio) propionate. Infect Immun. 1992;60(2):584-9.
12. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet. 2003;361(9372):1902-4.
13. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi MP, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007;25(Suppl 1):A101-7.
14. Chataway J, Brusoni S, Cacciatori E, Hanlin R, Orsenigo L. The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: a public/private partnership as knowledge broker and integrator. European Journal of Development Research. 2007;19(1):100-17.
15. Brooks A, Wells W, McLean T, Khanna R, Coghlan R, Mertenskoetter T, et al. Ensuring that developing countries have access to new healthcare products: the role of product development partnerships. Innovative Strategy Today. 2009;3:1-5.
16. Frew SE, Liu VY, Singer PA. A business plan to help the "global south" in its fight against neglected diseases. Health Aff (Millwood). 2009;28(6):1760-73.
17. The regulatory function that the WHO exercised in prequalifying the vaccine was kept behind a firewall from the WHO staff involved in the meningitis vaccine partnership. Had the regulators lessened their standards because of the WHO's participation in the vaccine's development, they would have been jeopardizing rather than enhancing the WHO's role in public health.
18. Yadav P, Stapleton O, Van Wassenhove L. A decision framework for the access strategy of medicines for malaria venture. New York (NY): INSEAD; 2009. INSEAD Working Paper No. 2009/41/TOM/ISIC.